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Crotalicidin (Ctn), a cathelicidin-related peptide from the
venom of a South American rattlesnake, possesses potent anti-
microbial, antitumor, and antifungal properties. Previously, we
have shown that its C-terminal fragment, Ctn(15–34), retains
the antimicrobial and antitumor activities but is less toxic to
healthy cells and has improved serum stability. Here, we inves-
tigated the mechanisms of action of Ctn and Ctn(15–34) against
Gram-negative bacteria. Both peptides were bactericidal, killing
90% of Escherichia coli and Pseudomonas aeruginosa cells
within 90 –120 and 5–30 min, respectively. Studies of  potential
at the bacterial cell membrane suggested that both peptides
accumulate at and neutralize negative charges on the bacterial
surface. Flow cytometry experiments confirmed that both pep-
tides permeabilize the bacterial cell membrane but suggested
slightly different mechanisms of action. Ctn(15–34) permeabi-
lized the membrane immediately upon addition to the cells,
whereas Ctn had a lag phase before inducing membrane damage
and exhibited more complex cell-killing activity, probably be-
cause of two different modes of membrane permeabilization.
Using surface plasmon resonance and leakage assays with model
vesicles, we confirmed that Ctn(15–34) binds to and disrupts
lipid membranes and also observed that Ctn(15–34) has a pref-
erence for vesicles that mimic bacterial or tumor cell mem-
branes. Atomic force microscopy visualized the effect of these
peptides on bacterial cells, and confocal microscopy confirmed
their localization on the bacterial surface. Our studies shed light
onto the antimicrobial mechanisms of Ctn and Ctn(15–34), sug-
gesting Ctn(15–34) as a promising lead for development as an
antibacterial/antitumor agent.
New antimicrobial drugs are urgently needed to address the
growing challenge of bacterial resistance to existing antibiotics.
Misuse of classical antibiotics has increased the number of
superbugs and created a critical situation whereby previously
controlled pathogens could in the future cause major morbidity
or mortality (1, 2). This alarming growth of multidrug-resistant
pathogens has prompted an intensive search for anti-infective
drugs with novel mechanisms of action (3, 4). In particular,
antimicrobial peptides (AMPs)9 have emerged as promising
alternatives due to their broad-spectrum activity (including
superbugs), selectivity, and mechanisms of action that poten-
tially hinder the development of resistance (5).
AMPs are ancient weapons of the host defense machinery,
present in all life domains (6). Although they can act in several
possible ways to accomplish microbial cell death (e.g. mem-
brane disruption, apoptosis induction, and internal target inhi-
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bition) (7, 8), an initial common step in the process is their
recruitment onto the bacterial cell surface (9, 10). Accordingly,
most AMPs display fairly conserved structural and physico-
chemical properties, such as positive net charge, high content
of hydrophobic amino acid residues, or amphipathic structure,
all favoring interaction with and insertion into membranes (11,
12). Cathelicidins are a large family of AMPs whose unifying
feature is the presence of a conserved cathelin (cathepsin L
inhibitor) domain at the N terminus. In contrast, their C-ter-
minal domains contain a mature and active AMP and display
high inter- and intraspecies diversity (13). Cathelicidins have
been shown to be active against a broad range of targets, includ-
ing bacteria, enveloped viruses, and fungi (14). In addition to
causing direct pathogen killing, cathelicidins can modulate the
immune response by assisting with pathogen clearance (15).
Cathelicidins have been isolated from a wide range of organ-
isms, including mammals (16 –18), birds (19), fish (20), frogs
(21), and marine (22) and terrestrial snakes (23–25).
We recently identified a new family of cathelicidin-like pep-
tides named vipericidins in the venom glands of various South
American pit viper snakes and experimentally validated them
as AMPs (26). Crotalicidin (Ctn), the most active vipericidin, is
a 34-residue helical peptide found in Crotalus durissus terrifi-
cus and was selected for further study. Ctn displays powerful
antimicrobial, as well as antitumor and antifungal, activity.
However, it is moderately hemolytic and unstable in serum (27,
28). To overcome these limitations, a rational dissection of
the Ctn sequence was undertaken, aimed at identifying active
motifs with enhanced properties. The search produced as main
lead Ctn(15–34), a structurally disordered 20-mer that spans
the C terminus and replicates the antibacterial and antitumor
activities of the parental peptide but is less toxic toward healthy
cells and significantly more stable in human serum (27). Inves-
tigating the mechanism of action on bacteria of both Ctn and
Ctn(15–34) is of considerable interest, particularly given the
potential therapeutic applications of the latter peptide.
In this study, the mode of action of Ctn and Ctn(15–34)
toward two Gram-negative bacterial species was investigated in
detail. We determined bactericidal concentrations and quanti-
tative kinetics of cell death and measured peptide accumulation
on bacterial cell surfaces. Combining flow cytometry and col-
ony count procedures, we established that bacterial death is
accomplished by membrane disruption. We also monitored
peptide uptake and membrane permeabilization in real time to
ascertain whether both effects are achieved simultaneously or
peptide pre-accumulation precedes loss of viability. To visual-
ize peptide localization and structural damage on bacteria sur-
face, we carried out confocal and atomic force microscopy
experiments. Furthermore, to gain insights into the cell selec-
tivity and the ability to disrupt lipid bilayers of the fragment
Ctn(15–34), we performed experiments with model vesicles
mimicking healthy human and bacterial cell membranes.
Altogether, our results provide strong evidence that Ctn and
Ctn(15–34) act by inducing disruption of the bacterial cell; they
also exemplify how a set of optimized methodologies can be




The amino acid sequences in Table 1 were prepared in C-ter-
minal amide form by Fmoc (N-(9-fluorenyl)methoxycarbonyl)
solid-phase synthesis and purified to 95% purity (see Fig. S1
for HPLC and MS data). For the N-terminal rhodamine B
(RhB)-labeled peptides, the two peaks observed in the chro-
matograms of purified compounds (Fig. S1a) are due to RhB
atropisomerism. The overall hydrophobicity of unlabeled and
RhB-labeled peptides can be compared by the percentage of
acetonitrile (ACN) at which they elute in HPLC (Table 1). Val-
ues for unlabeled Ctn and Ctn(15–34) were 30.9 and 30.3%
ACN, respectively, whereas RhB-labeled versions eluted at
34.7 and 34.2% ACN, respectively, underlining the increase in
hydrophobicity brought about by RhB labeling.
Antibacterial and bactericidal activity
We evaluated the antimicrobial activity of Ctn and Ctn(15–
34) against two Gram-negative bacterial strains: Escherichia
coli ATCC 25922 (E. coli) and Pseudomonas aeruginosa ATCC
27853 (P. aeruginosa). As shown in Table 2, Ctn has the lowest
minimal inhibitory concentration (MIC) for E. coli as well as for
P. aeruginosa (0.78 and 1.56 M, respectively). Ctn(15–34) also
has a low MIC for E. coli (3.13 M), but the concentration
required to prevent P. aeruginosa visible growth is higher (12.5
M). To determine whether the peptides were bactericidal or
bacteriostatic, the minimal bactericidal concentrations (MBCs)
were also determined (Table 2). The data show both Ctn
and Ctn(15–34) to be bactericidal, as MBCs exceed MICs by
2-fold (29). The MIC/MBC determinations reveal that more
peptide is required for bacterial death when higher bacterial
inocula are used. This difference is significant for E. coli, for
Table 1
Peptides used in this study









Da Da % min %
Ctnf KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF-amide 4151.39 4152.45 98 15–40 9.556 30.9
RhB-Ctn RhB-KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF-amide 4576.94 4575.97 99 20–40 10.997 34.7
Ctn(15–34) KKRLKKIFKKPMVIGVTIPF-amide 2371.11 2371.23 99 10–40 10.131 30.3
RhB-Ctn(15–34) RhB-KKRLKKIFKKPMVIGVTIPF-amide 2796.66 2795.90 98 20–40 10.670 34.2
a Theoretical molecular mass was calculated using GPMAW version 8.10.
b Experimental molecular mass was determined from the MS spectra shown in Fig. S1b.
c Peptide purity was estimated by peak integration of the analytical HPLC chromatograms shown in Fig. S1a.
d ACN gradient over 15 min used to run the analytical HPLC. Range indicates the initial and final ACN concentrations.
e Percentage of ACN corresponding to the eluted peptide, calculated from the gradient used and the retention time.
f Protein Data Bank accession code of Ctn: 2MWT.
Membrane-disruptive effect of Ctn and Ctn(15–34)
J. Biol. Chem. (2018) 293(5) 1536 –1549 1537
 at Institut Pasteur - C
eR









which up to 3 times more peptide is needed. These results
support previous observations suggesting that the therapeutic
effect of AMPs depends on the peptide/cell ratio rather than
directly on peptide concentration (30, 31). In tune with this
suggestion, and to avoid the results being influenced by the
use of different peptide/cell ratios, peptide concentrations for
mechanism-of-action studies were adjusted to the bacterial
inoculum used for each specific experiment.
Time-dependent bacterial death
The killing kinetics of E. coli and P. aeruginosa by Ctn and
Ctn(15–34) at their respective MBCs was evaluated using a
time-kill assay. The results in Fig. 1a show that for both pep-
tides, a bactericidal effect (99.9% reduction of bacterial viabil-
ity) against E. coli is observed within 4 h. At 90 min, Ctn kills
90% of bacteria, whereas Ctn(15–34) needs 120 min for a
similar effect. Ctn and Ctn(15–34) are faster at killing P. aerugi-
nosa, requiring only 5 or 30 min for 90% cell death, respectively,
with bactericidal effect observed at 15 and 90 min, respectively.
This relatively fast effect against E. coli, even faster against
P. aeruginosa, suggests that both peptides act by direct damage
to the bacterial membrane rather than by inhibition of an inter-
nal target.
Membrane surface charge neutralization
To investigate whether surface charge can be neutralized by
the accumulation of the peptides at the membrane of E. coli or
P. aeruginosa,  potential measurements were carried out. The
results show that, as expected (32, 33), in the absence of peptide,
both bacteria possess a negative potential (Fig. 1b, 24 mV
for E. coli and 21 mV for P. aeruginosa). In the presence of
increasing peptide concentrations, a shift to positive  potential
values is observed. In E. coli, complete neutralization of the
surface charge occurs at 0.78 –3.13 M Ctn and 1.56 –3.13
M Ctn(15–34), whereas for P. aeruginosa, total surface
charge neutralization is reached at 0.78 –3.13 M Ctn and
3.13– 6.25 M Ctn(15–34). For both bacteria, membrane
neutralization occurs at concentrations below the MIC/
MBC of either peptide.
Membrane permeabilization and viability correlation studies
To clarify whether E. coli and P. aeruginosa death induced by
Ctn and Ctn(15–34) is due to direct membrane disruption,
correlation between membrane permeabilization and bacterial
viability was studied. To this end, a flow cytometry assay (FCA)
with SYTOX Green to examine membrane permeabilization
and a plate colony count to quantify viable cells were per-
formed. As a cell-impermeable nucleic acid stain that only
labels bacteria with compromised plasma membrane, SYTOX
Green is a useful tool in bacterial viability studies. As shown in
Fig. 2, an increased percentage of bacterial cells with SYTOX
Green-permeable membrane is accompanied by a decrease in
cell viability by the colony count method. FCA histograms on
the SYTOX Green channel (Fig. 2a) shift to higher fluores-
cence intensities indicative of E. coli and P. aeruginosa mem-
brane disruption with increasing peptide concentration. Nega-
tive and positive controls (live and dead bacteria; black and gray
histograms, respectively) were used to define gates and calcu-
late permeabilization percentages, shown in Fig. 2b along with
the viability percentages obtained in the colony count assay. A
direct correlation between both sets of data (Fig. 2b) confirms
that antibacterial activity of Ctn and Ctn(15–34) is mediated by
membrane permeabilization.
To correlate the membrane permeabilization effect with
peptide uptake (including both membrane-bound and intracel-
lularly internalized), a parallel FCA experiment was performed
with RhB-labeled versions of both peptides. From the SYTOX
Green and RhB channel readings (Fig. S2, a and b), the percent-
ages of permeabilized and of peptide-internalizing cells, respec-
tively, were determined (Fig. S2c). For both Ctn and Ctn(15–
34), an increase in E. coli permeabilization coincides with
increased peptide uptake, suggesting a direct correlation be-
tween the membrane damage observed and peptide entry/
binding. The dose–response curve for RhB-Ctn (Fig. S2c, con-
tinuous red line) is similar to that for unlabeled Ctn (Fig. 2b,
continuous red line), suggesting that RhB does not interfere
with the peptide effect. In contrast, the profiles for RhB-labeled
(Fig. S2c, continuous blue line) and unlabeled Ctn(15–34) (Fig.
2b, continuous blue line) are different. Whereas the latter
induces 50% permeabilization in the 6.25–12.5 M range, the
percentage rises to 80% for the RhB-labeled analogue at similar
concentrations. Moreover, at higher (25–100 M) concentra-
tions, a decrease in membrane permeabilization and uptake of
RhB-Ctn(15–34) occurs, an effect not observed for unlabeled
Ctn(15–34). This probably reflects a loss in integrity of the bac-
terial cell, no longer capable of retaining the labeled peptide
within, and with its DNA (SYTOX Green target) either dam-
aged or leaking out. The observation of N-terminal RhB label
interfering with the activity of Ctn(15–34) calls for caution in
extrapolating results from labeled to unlabeled versions of this
peptide.
Table 2
MIC and MBC of Ctn and Ctn(15–34) against two standard Gram-negative bacterial strains
5  105-cfu/ml or 107-cfu/ml bacterial suspensions were incubated with different concentrations of Ctn or Ctn(15–34). MIC was determined as the lowest peptide
concentration that prevented visible bacterial growth. MBC was defined as the minimal peptide concentration where 99.9% bacteria death of the initial inoculum was
observed.
Peptide
E. coli ATCC 25922 P. aeruginosa ATCC 27853
5  105 cfu/ml 107 cfu/ml 5  105 cfu/ml 107 cfu/ml
MIC (M)
Ctn 0.78 6.25 1.56 3.13
Ctn(15–34) 3.13 50 12.5 25
MBC (M)
Ctn 1.56 6.25 3.13 3.13
Ctn(15–34) 6.25 50 25–50 25
Membrane-disruptive effect of Ctn and Ctn(15–34)
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Time-resolved peptide uptake and bacterial death
Changes in membrane permeabilization and peptide uptake
were monitored by a time-resolved flow cytometry assay, which
allows a more accurate study of the kinetics of peptide effect,
compared with kinetic studies based on end-point sampling.
We studied the membrane permeabilization of E. coli using
SYTOX Green dye right after Ctn or Ctn(15–34) addition,
monitoring the changes from negative to positive gates for 90
min. Fig. 3 (a and b) shows time-course results and negative and
positive controls (for the whole acquisition, see Movies S1a and
S1b for Ctn and Ctn(15–34), respectively). As detailed under
“Experimental procedures,” data from the FCA histograms
were used to generate the kinetic curves on Fig. 3c. Data were
fitted using the two-state kinetic model described previously
for other AMPs (34), assuming that peptide-bacteria interac-
tion consists of an initial binding step, followed by permeabili-
zation of the membrane.
Although both peptides induce permeabilization of 90% of
bacteria after 90 min (Fig. 3c), the process differs between pep-
tides at the early stages; based on the tendency of the experi-
mental data, Ctn(15–34) seems to start killing bacteria right
after its addition, and the permeabilization takes place in a sin-
gle process. In contrast, Ctn shows an initial lag phase. Fitting of
the kinetic data to a two-state model results in statistically poor
residuals for some time intervals (Fig. S3), suggesting that
for both peptides, permeabilization is more complex than as
assumed by the model. An additional slow event leading to per-
meabilization is suggested because the data deviate from the fit
at longer times. In contrast, the fit is quite acceptable at shorter
times. k0, the membrane attachment rate constant, is higher for
Ctn(15–34) than for Ctn (2  102 s1 versus 1  103 s1) as
well as the permeabilization rate constant (1  103 s1 versus
9  104 s1). Cooperativity is not observed in either case
(f  0), contrary to other AMPs (34).
To determine whether permeabilization is concomitant with
internalization, kinetic studies with RhB-labeled peptides were
run. Correlograms (Fig. S4a) at different time points show the
changes recorded on the SYTOX Green and RhB channels
(see Movies S2a and S2b for the entire acquisition of RhB-Ctn
and RhB-Ctn(15–34), respectively). Kinetic curves (Fig. S4c)
show both peptides becoming gradually bound to and/or inter-
nalized into the cells until an equilibrium is reached, but the
uptake of RhB-Ctn(15–34) is faster than that of RhB-Ctn. Inter-
estingly, RhB-Ctn(15–34) uptake precedes bacterial membrane
damage, suggesting that peptide accumulation up to an effec-
tive threshold is necessary to trigger membrane permeabiliza-
tion. In contrast, RhB-Ctn uptake shortly precedes membrane
permeabilization, confirming that membrane becomes per-
meabilized as Ctn molecules are recruited to the surface.
Peptide distribution in bacteria
To investigate how peptides are localized within the bacteria,
confocal microscopy was done on E. coli after incubation with
RhB-labeled Ctn and Ctn(15–34) for 90 min. Images were also
acquired using the SYTOX Green dye, to correlate peptide
location with bacterial membrane permeabilization. Single-cell
images acquired using the superresolution Airyscan mode are
shown in Fig. 4a. Both peptides are preferentially localized
around the bacteria, probably on the membrane. In some
images, it was also possible to observe both peptides apparently
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Figure 1. Time-dependent bacterial death and bacterial surface neutralization induced by Ctn and Ctn(15–34). a, time-killing curves for E. coli and
P. aeruginosa in the presence of Ctn and Ctn(15–34). 5  105 cfu/ml bacterial suspensions were incubated at 37 °C with Ctn (circles) or Ctn(15–34) (inverted
triangles) at their MBC. At different time points, aliquots were collected, diluted, and spread onto trypticase soy agar plates. Bacterial colonies were counted
after 24-h incubation at 37 °C, and viable bacteria are reported as a percentage of the control without peptide. Data correspond to mean  S.D. (error bars) of
three independent experiments. b,  potential measurements of E. coli and P. aeruginosa in the presence or absence of peptides. Ctn (circles) or Ctn(15–34)
(inverted triangles) at different concentrations were added to 107 cfu/ml bacterial suspensions and allowed to equilibrate for 15 min at 25 °C, and 15 measure-
ments were acquired.  potential (mV) was estimated using the Smoluchowski equation (55).
Membrane-disruptive effect of Ctn and Ctn(15–34)
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co-localizing with SYTOX Green (as shown in the fluores-
cence distribution plot; Fig. 4a). This suggests partial internal-
ization and binding to DNA by the peptide, but the finding is
not general for all bacteria. Images acquired in the normal con-
focal mode (Fig. S5) show untreated controls and bacteria
treated with non-labeled peptides.
Imaging peptide effect on bacterial cells
To visualize structural changes on E. coli induced by Ctn and
Ctn(15–34), individual bacteria were imaged by AFM after
incubation with peptides at their MBC. As shown in Fig. 4b,
both peptides induce major morphological alterations. Com-
pared with control, the typical shape of the bacteria is lost, and
substantial shrinkage, particularly at the central region, is
observed. Additionally, treatment with either peptide also
induces leakage of cytoplasmic content, as shown by images of
bacterial surroundings. Cross-line profiles on Fig. 4b allow to
visualize the location of three (for Ctn) or two (for Ctn(15–34))
protuberances in the septal poles of the bacteria and the afore-
mentioned shrinkage at the middle.
Ability of Ctn(15–34) to target the bacterial surface
Gram-positive bacteria have lipoteichoic acid (LTA) at the
membrane surface, whereas Gram-negative bacteria have lipo-
polysaccharide (LPS) (35). Both LTA and LPS are negatively
charged and likely to be involved in the first contact of peptides
with bacterial cells. To examine whether Ctn(15–34) and its labeled
analogue RhB-Ctn(15–34) are able to bind to these molecules, we
have used a Limulus amebocyte lysate (LAL) assay, which detects
the presence of non-neutralized LTA and LPS (36). Results in Fig.
5a show that RhB-Ctn(15–34) neutralizes both LPS and LTA,
whereas Ctn(15–34) is less efficient in doing it, especially for LTA.
Interaction of Ctn(15–34) with model membranes
The ability of Ctn(15–34) to bind model membranes com-
posed of different lipid mixtures was examined by surface plas-
Figure 2. Bacterial cell viability and membrane permeabilization of E. coli and P. aeruginosa upon treatment with Ctn and Ctn(15–34). 5  105 cfu/ml
bacterial suspensions were incubated at 37 °C with increasing peptide concentrations of Ctn (red) or Ctn(15–34) (blue). a, histograms on the SYTOX Green
channel detected by flow cytometry. Negative (live bacteria) and positive (dead bacteria) controls, used to define gates, are represented in black and gray,
respectively. b, viable bacteria (dotted lines) and permeabilized bacteria (solid lines) are reported as a percentage of the control. Data correspond to mean  S.D.
(error bars) of three independent experiments.
Membrane-disruptive effect of Ctn and Ctn(15–34)
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mon resonance (SPR). Previous studies suggested a preferential
binding of Ctn(15–34) to bacteria and cancer cells rather than
healthy eukaryotic cells (27). In view of this, a number of phos-
pholipid compositions mimicking various types of cell mem-
branes were assayed. Vesicles composed of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), a zwitterionic
phospholipid forming neutral, fluid lipid bilayers at 25 °C, were
compared with membranes made of POPC/sphingomyelin
(SM)/cholesterol (Chol) (POPC/SM/Chol; 27:33:40 molar
ratio), which forms bilayers with the liquid-ordered phase.
POPC mimics the neutral fluid portions, whereas POPC/
Chol/SM simulates the more-ordered raftlike portions of the
outer leaflet in healthy human cells (37, 38). The inner leaflet of
healthy human cell plasma membranes possesses zwitterionic
phosphatidylethanolamine (PE)-, anionic phosphatidylser-
ine (PS)-, and phosphatidylcholine (PC)-phospholipids (37,
38); thus, the mixture POPC/1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho-L-serine (POPS)/1-palmitoyl-2-oleoyl-sn-glycero-
phospho-L-ethanolamine (POPE) (60:20:20) has been included
to mimic the inner leaflet of healthy cell membranes. Tumor
cells possess larger proportions of negatively charged phospho-
lipids exposed to the outer leaflet than healthy cells; therefore,
the potential effect of negatively charged phospholipids was
further examined by testing the affinity to membranes com-
posed of POPC/POPS in 80:20 or 60:40 proportions. Finally,
bacterial cell membranes have high negative charge and large
proportions of phosphatidylgylcerol (PG)-phospholipids; to
mimic them, vesicles composed of POPC/POPG (80:20 or
60:40) or of an E. coli polar extract that contains a mixture of PE-
phospholipids, PG-phospholipids, and cardiolipin were prepared.
Figure 3. Time-resolved bacterial membrane permeabilization. Ctn (red) or Ctn(15–34) (blue) at its MBC was added to 107 cfu/ml E. coli suspensions.
Changes on the SYTOX Green channel were monitorized during 90 min immediately after the peptide addition. a, flow cytometry histograms on the SYTOX
Green channel at different time points in the presence of Ctn and Ctn(15–34). Pn is the percentage of permeabilization at each time interval (n) (in s). b, flow
cytometry histograms on the SYTOX Green channel for the negative (live bacteria) and positive (dead bacteria) controls, used to define gates. c, percentages
of permeabilized bacteria over time after the addition of the peptides. Data were normalized by controls, corrected using the calibration curve shown in Fig.
S8a, and fitted with the two-state model (34) as described under “Experimental procedures.” The kinetic curve for the untreated control shown in Fig. S8b
demonstrates that bacteria remain alive during the whole acquisition, and the changes observed in c are due to the peptide activity.
Membrane-disruptive effect of Ctn and Ctn(15–34)
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Sensorgrams obtained with zwitterionic lipid systems (i.e.
POPC and POPC/Chol/SM)) (Fig. 5b, left) showed rapid disso-
ciation, suggesting that Ctn(15–34) is rapidly removed from
neutral membranes, and dose–response curves (Fig. 5b, right)
showed that Ctn(15–34) has a weak overall affinity for these
lipid membranes. No significant differences were detected
between fluid or liquid-ordered phases, suggesting an overall
weak affinity for neutral membranes. In contrast, Ctn(15–34)
has higher affinity for vesicles made of anionic phospholipids,
as suggested by dose-response curves and sensorgrams ob-
tained with POPC/POPS and POPC/POPG (see Fig. 5b and
Table 3). Improved affinity is observed with higher content of
anionic lipids (e.g. compare POPC with POPC/POPS (80:20)
and with POPC/POPS (60:40)). The addition of PE-phospho-
lipids to anionic membranes did not improve Ctn(15–34) bind-
ing, as shown with POPC/POPS (80:20) versus POPC/POPE/
POPS (60:20:20). Although an improvement in affinity was
observed for all anionic membranes, Ctn(15–34) has better
affinity for POPS than for POPG, as demonstrated by compar-
ing its binding with POPC/POPG (60:40) and POPC/POPS (60:
40) (Fig. 5b).
To investigate whether N-terminal RhB derivatization alters
the binding behavior of Ctn(15–34), the labeled and unlabeled
versions were compared for binding to POPC and POPC/POPS
(80:20). Similar to the case for bacterial cells (Fig. 2 and Fig. 2),
the RhB version shows higher affinity for both neutral and ani-
onic membranes (Fig. S6).
Membrane-disrupting properties of Ctn(15–34)
To examine whether peptides disturb pure lipid bilayers, ves-
icles loaded with carboxyfluorescein (CF) were incubated with
various concentrations of Ctn(15–34) or RhB-Ctn(15–34). Fig.
5c shows that Ctn(15–34) does not induce dye leakage from
neutral POPC vesicles, yet it disrupts negatively charged
POPC/POPS (80:20) vesicles in a dose-dependent manner
(LC50 2.17  0.36 M). In agreement with an overall increase in
affinity for the membrane, RhB-Ctn(15–34) disrupts vesicles,
including zwitterionic membranes, with much higher effi-
Figure 4. Peptide localization and structural changes on E. coli cell surface. a, confocal point scanning microscopy images of E. coli upon treatment with
RhB-Ctn and RhB-Ctn(15–34). Peptides were added to 107 cfu/ml E. coli suspensions at their MBC. The fluorescence emission intensity of RhB (red signal) allows
detection of the peptides’ distribution. Fluorescence emission intensity of SYTOX Green (green signal) allows detection of bacterial membrane permeabili-
zation. Normalized fluorescence intensity (for red and green signals) along the white line indicated in the merged superposition image is also shown. b, atomic
force microscopy images of untreated E. coli suspension at 107 cfu/ml or after incubation with Ctn and Ctn(15–34) at their MBC. Three-dimensional projections
(left) and height images (middle) of E. coli cells and the profile (right) of the cross-line on height images are shown.
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ciency than its unlabeled version (LC50 0.24  0.02 M with
POPC and 0.26  0.02 M with POPC/POPS (80:20)) (see Fig.
5c). Both peptides have a similar effect on POPC/POPCS (80:
20) vesicles at 5, 10, and 15 min (Fig. S7), suggesting that dis-
ruption takes place within the first 5 min.
Toxicity to human red blood cells
The hemolytic properties of Ctn(15–34) and RhB-Ctn(15–
34) were tested in human red blood cells (RBCs). Ctn(15–34) is
not hemolytic up to 64 M when tested against 0.25% (v/v) of
RBCs (Fig. 5d). The lack of toxicity of Ctn(15–34) against RBCs
is in agreement with its low affinity and inability to disturb
neutral model membranes. On the other hand, derivatization of
the peptide with RhB makes the peptide toxic, as shown with
RhB-Ctn(15–34) (HC50 4.33  0.18 M) and is in agreement
with this peptide possessing high affinity and the ability to dis-
rupt lipid membranes.
Discussion
The aim of this work was to gain insights into the antimicro-
bial mechanisms of Ctn, an AMP derived from the venom gland
of the rattlesnake Crotalus durissus terrificus, and of its frag-
ment Ctn(15–34). Previous studies demonstrated that Ctn is
toxic against bacteria, fungi, tumor, and healthy cells (26, 28). In
contrast, Ctn(15–34) kills Gram-negative bacteria, fungi, and
tumor cells but not healthy eukaryotic cells. Moreover, Ctn(15–
34) has remarkable stability in human serum and is 40% smaller
than Ctn (20 versus 34 amino acid residues) (27). For this reason,
Ctn(15–34) is regarded as a promising anti-infective lead. How-
ever, its mechanism of action had not been examined until now.
To investigate the mode of action, we compared the anti-
microbial potency and ability to disrupt membranes of Ctn
and Ctn(15–34), using Gram-negative E. coli and P. aerugi-
nosa as model organisms. We confirmed that both peptides
are bactericidal at low micromolar concentrations (Table 1)
and demonstrated that bacterial death is accomplished
remarkably fast (Fig. 1a), particularly against P. aeruginosa.
A fast induction of bacterial death is normally associated
with loss of physical integrity of the membrane (39), as
described previously for AMPs such as melittin (40), C16G2
(41), vAMP 059, and vCPP 2319 (42). The current results
confirm a mode of action related to membrane disruption
Figure 5. Interaction of Ctn(15–34) and RhB-Ctn(15–34) with LPS, LTA, model membranes, and RBCs. a, binding of Ctn(15–34) and of RhB-Ctn(15–34) to
LTA and LPS as examined using the LAL assay. The concentration of RhB-Ctn(15–34) to neutralize 50% of LTA and LPS is 0.22 and 8.26 M, respectively.
Ctn(15–34) requires 32 M to neutralize both LTA and LPS. b, binding of Ctn(15–34) to model membranes followed by surface plasmon resonance. Peptide
samples were injected over lipid bilayer deposited onto an L1 chip surface; sensorgrams (left) obtained upon injection of 38 M peptide over a particular lipid
bilayer for 180 s (association phase) and the dissociation followed for 600 s (dissociation phase). Shown is the amount of Ctn(15–34) (right) obtained at the end
of association phase (t  170 s) upon injection of various peptide concentrations. The signal of sensorgrams and dose–response curves were normalized to
peptide/lipid ratios (P/L, mol/mol) by converting response units into mol of peptide and normalized for the amount of lipid deposited onto the lipid surface (1
response unit  1 pg/mm2 of peptide or lipid). c, membrane disruption induced by Ctn(15–34) and RhB-Ctn(15–34). The percentage of membrane leakage was
determined by CF dequenching. LUVs composed of POPC or POPC/POPS (80:20) with total lipid concentration of 5 M were incubated with various concen-
trations of peptide. Melittin, a membrane-disrupting peptide, was included as a positive control. d, toxicity against RBCs induced by Ctn(15–34) and RhB-
Ctn(15–34). A suspension of RBCs (0.25%, v/v) was incubated with various concentrations of peptides. Percentage of hemolysis was detected by absorbance
of hemoglobin released into the supernatant. Melittin was included as a control peptide with hemolytic properties. Error bars, S.D.
Table 3
Affinity of Ctn(15–34) for different lipid systems as followed by surface
plasmon resonance
P/Lmax (mol/mol) is the maximum binding of Ctn(15–34) for a given lipid system.
P/Lmax was calculated by fitting the dose–response curves shown in Fig. 5b (right)
with one-site specific binding with the Hill slope equation.
Lipid system P/Lmax
 101 mol/mol
POPC 0.33  0.05
POPC/Chol/SM (27:33:40) 0.37  0.02
E. coli polar extract 0.77  0.04
POPC/POPS (80:20) 0.83  0.11
POPC/POPS (60:20) 1.76  0.15
POPC/POPS/POPE (60:20:20) 0.65  0.09
POPC/POPG (80:20) 0.63  0.07
POPC/POPG (60:40) 1.35  0.15
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and suggest different stages in the permeabilization process
(Fig. 6): (Stage 1) initial peptide recruitment; (Stage 2) pep-
tide accumulation; and (Stage 3) cell death by membrane
disruption.
Stage 1: Initial peptide recruitment
There is wide agreement that AMPs are usually drawn to
microbial surfaces by electrostatic attraction between cationic
(Lys, Arg, and His) residues in the peptide and anionic
components in the bacterial surface, such as LPS and LTA on
Gram-negative or Gram-positive surfaces, respectively, and/or
anionic phospholipids (PG and cardiolipin) in the plasma mem-
brane (7). In the present case, the high cationicity of both Ctn and
Ctn(15–34) (net charge 	16 and 	8, respectively) and their pref-
erential action on Gram-negative bacteria suggest that both pep-
tides might bind LPS, as proposed for other snake-derived cathe-
licidins, such as Pb-CATH (43) and HC-CATH (22). As shown in
Fig. 5a, Ctn(15–34) is not highly efficient at neutralizing both LPS
and LTA, but even so, the binding is higher for LPS than for LTA,
in concordance with its preference for Gram-negative bacteria.
The fact that both peptides show a preference for cardiolipin (see
below in AFM results) also reinforces an electrostatically driven
initial recruitment step.
Stage 2: Peptide accumulation
Build-up of Ctn and Ctn(15–34) onto the bacterial surface
was confirmed by  potential studies, because the negatively
charged surface of both E. coli and P. aeruginosa was neutral-
ized by increasing peptide concentrations, which caused a shift
to positive  potential values (Fig. 1b). In all cases, neutralization
occurred at concentrations lower than MIC or MBC (Fig. 1b),
suggesting that surface charge equalization is not enough and
that more peptide is necessary to induce bacterial death, which
takes place after a threshold concentration of Ctn and Ctn(15–
34) on the bacteria surface has been reached and peptides can
begin to cross/enter the membrane.
Stage 3: Cell death by membrane disruption
Bacterial death results from membrane disruption and con-
sequent loss of functionality. FCA data in Fig. 2 and Fig. S2 show
a direct correlation between peptide uptake, membrane per-
meabilization, and viability loss. A mechanism dependent on
the ability to target the membrane was also confirmed by imag-
ing techniques. AFM studies showed important disturbances in
the E. coli surface upon incubation with Ctn and Ctn(15–34)
(Fig. 4b). The leakage of cytoplasmic content observed after
peptide treatment is in agreement with a lytic mechanism of
action, and the shrinkage observed in the middle region of the
Figure 6. Mechanism of action proposed for Ctn and Ctn(15–34). Both Ctn and Ctn(15–34) present a membrane-disruptive effect comprising three main steps:
(Stage 1) initial peptide recruitment due to electrostatic attractions between cationic residues of peptide and anionic molecules in the bacterial outer membrane;
(Stage 2) accumulation of peptide on the surface of the membrane up to an effective threshold concentration; and (Stage 3) bacterial cell death by membrane
disruption.
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bacteria could be due to preferential accumulation of peptides
in cardiolipin-rich domains, namely in the apical and septal
area of the cell (44), as described previously for other AMPs
(32). Confocal microscopy experiments found RhB peptides in
the periphery of E. coli bacteria (Fig. 4a), probably located on
the membrane, in tune with the membrane-disruption hypoth-
esis, although they were also found internalized inside cells in
some cases. Thus, we propose that both peptides are initially
recruited and accumulate around the surface until a threshold
concentration is reached, after which they begin to enter/cross
the lipid bilayer, causing cell death.
The membrane-lytic mechanism proposed here for Ctn and
Ctn(15–34) is in agreement with results described for other
snake-derived, evolutionarily related cathelicidins (e.g. catheli-
cidin-BF (Cbf), a 30-residue AMP from the elapid snake Bun-
garus fascatus, also described as membrane-disruptive against
bacteria) (45, 46). Analogs Cbf-K16 and Cbf-A7A13, able to kill
multiresistant E. coli in a few hours, can also penetrate bacteria
cell membrane as well as bind to DNA (47), suggesting that
these peptides are not simply retained on the lipid bilayer. The
N-terminal fragment, BF-15, and its analog ZY13, both active
against resistant Candida albicans and less hemolytic than Cbf,
also act in a membrane-disruptive manner (48). The aforemen-
tioned Pb-CATH and HC-CATH also possess bacterial mem-
brane lytic properties (22, 43), and OH-CATH and NA-CATH,
two cathelicidins found in cobra species, possess 79% identity
with Ctn and are also membrane-active (24, 49).
Despite evidence suggesting a common membrane disrup-
tion mechanism for snake cathelicidins, how this process
unfolds over time is not well studied, in part due to the limited
information available by standard methods. To shed light on
this issue, we employed time-resolved flow cytometry (34, 50), a
high-resolution technique that allows monitoring peptide
uptake and membrane permeabilization over time. This is par-
ticularly relevant to membrane-lytic peptides, for which bind-
ing and accumulation on the bacterial surface are early-onset
events not easily monitored by end-point experiments. For
instance, FCA kinetic curves (Fig. 3) reveal differences unde-
tectable with the colony count method. Ctn(15–34) acts faster
than Ctn due to faster binding and membrane permeabilization
(Fig. 3). The slower stages in the action of Ctn cause a lag in its
kinetic curve, although no cooperativity is detected, which
demonstrates that common-sense reasoning that assigns lag
phase directly to positive cooperativity (34, 51, 52) might be an
oversimplification.
The mechanism of action of both Ctn and Ctn (15–34)
includes steps whose kinetic curves deviate from the two-state
model. Interestingly, the related NA-CATH cathelicidin seems
to switch its mechanism of action from membrane disruption
to pore-based lysis in a biphasic model, mimicking the E. coli
membrane with an impact on kinetics similar to that described
for Ctn (49). Given the high structural similarities between both
peptides (an N-terminal -helical segment followed by a disor-
dered tail) (27, 53), it is plausible that Ctn may act similarly, and
such behavior would explain the complex cell death kinetic pat-
tern here reported. This dual behavior might be tentatively
related to the composite structure (-helix plus random tail) of
both NA-CATH and Ctn, each moiety of the peptide embed-
ding into the membrane in a different fashion, as suggested for
NA-CATH (49). The fact that removal of the N-terminal helix
of Ctn to give Ctn(15–34) results in a simplified killing mecha-
nism corroborates our hypothesis.
RhB-labeled versions of Ctn and Ctn(15–34) show different
uptake kinetics relative to unlabeled peptides (Fig. S4). RhB-
Ctn binds slower than RhB-Ctn(15–34) (Fig. S4), but mem-
brane permeabilization is much faster once the peptides are
bound. Use of RhB-labeled Ctn(15–34) (Fig. S4) made possible
the monitoring of peptide attachment to bacteria simultane-
ously with membrane permeabilization. RhB fluorophore emis-
sion confirms that RhB-Ctn(15–34) binds faster to membranes
than RhB-Ctn, in agreement with the two-state model analyses
for both peptides (k0  7  104 s1 versus k0  2  102 s1).
In contrast, upon membrane binding, membrane permeabiliza-
tion is faster for RhB-Ctn (k2  1  102 s1 versus k2  1 
103 s1). For both labeled peptides, f  0, which shows that no
cooperativity exists. In general, kinetic and membrane-affinity
results for RhB-Ctn(15–34) appear to be affected by RhB label-
ing (Fig. 5 (a, c, and d) and Figs. S2 and S6); hence, conclusions
cannot be extrapolated to the unlabeled version.
The previously described putative selectivity of Ctn(15–34)
for anionic domains (27) was corroborated by experiments with
model membranes showing a preference for anionic, particu-
larly PS-rich vesicles (Fig. 5b). LUV leakage (Fig. 5c) and RBC
hemolysis (Fig. 5d) studies show that Ctn(15–34) preferentially
interacts and disrupts vesicles mimicking bacterial and tumor
rather than healthy eukaryotic cells. These results are in agree-
ment with data from other snake cathelicidins (e.g. OH-
CATH), which suggest a crucial implication of the four N-ter-
minal amino acid residues in hemolytic activity (24).
In conclusion, by deploying a set of high-resolution method-
ologies, we have achieved accurate spatiotemporal character-
ization of events involved in the bactericidal action of Ctn and
Ctn(15–34) on E. coli and P. aeruginosa. The study sheds light
on the mechanism whereby the peptides accumulate and dis-
rupt bacterial and model membranes and reveals slight differ-
ences in their behavior, including different kinetics of access to
bacterial surfaces and different toxicity. By dissecting Ctn into
its Ctn(15–34) fragment, we have produced a smaller, simpler,
and more cost-efficient AMP displaying selectivity for bacteri-
al-like, PS-rich membranes and a simplified mechanism of
action. Taken together, our findings augur a promising role for
Ctn(15–34) as an anti-infective lead and, in a broader sense,
provide valuable insights into AMP lethal mechanisms that
should be useful in the design and development of antimicro-
bials against resistant bacteria.
Experimental procedures
Peptides
Peptides in Table 1 were assembled as C-terminal carboxam-
ides on Rink amide resin as described previously (27). For N-ter-
minal RhB coupling, the peptide-resin was N-deprotected with
piperidine/N,N-dimethylformamide (20:80, v/v) and treated with
a 5-fold molar excess of RhB/N,N
-diisopropylcarbodiimide (1:1
molar ratio) in dichloromethane, followed by extensive dich-
loromethane and N,N-dimethylformamide washes. Analytical
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reversed-phase HPLC, preparative HPLC, and LC-MS analyses
were as reported previously (27). Peptide stock solutions were pre-
pared in sterile Milli Q water and stored at 20 °C.
Antibacterial and bactericidal assays
The antimicrobial activity of Ctn and Ctn(15–34) was stud-
ied against Gram-negative reference strains E. coli ATCC
25922 and P. aeruginosa ATCC 27853. Minimal inhibitory and
bactericidal concentrations (MIC and MBC) were determined
by the broth microdilution method as described in document
M26-A of the Clinical and Laboratory Standards Institute (54).
Briefly, bacterial suspensions were prepared by the direct col-
ony suspension method into BBLTM Mueller Hinton II Broth
(cation-adjusted) medium (MHBII) (BD Biosciences) and incu-
bated for 18 h at 37 °C with 2-fold serial peptide dilutions on
96-well microtiter polystyrene plates (Corning Inc.). Final bac-
terial concentration was 5  105 cfu/ml or 107 cfu/ml, and
peptide concentrations were in the 0.1–100 M range. After
incubation, MIC values were determined as the lowest peptide
concentration preventing visible bacterial growth. MBC values
were subsequently determined as described previously (42). All
assays were performed in triplicate.
Time-kill curves
The time-dependent bactericidal effect of Ctn and Ctn(15–
34) were assessed against both E. coli and P. aeruginosa. Bacte-
rial suspensions prepared on MHBII at 5  105 cfu/ml were
treated with the peptides at a final concentration correspond-
ing to their MBC and incubated at 37 °C and 200 rpm. As
control, bacterial suspensions without peptide were prepared
under the same conditions. Aliquots of untreated and peptide-
treated bacterial suspensions were withdrawn at different time
points (t  5, 15, 30, 60, 90, 120, 180, and 240 min), serially diluted,
plated onto trypticase soy agar plates, and incubated at 37 °C. After
24 h, the number of bacterial colonies was counted, and viable
bacteria (in cfu/ml) at each t were calculated as percentage of the
untreated control at t0. The assay was performed in triplicate.
 potential
For the  potential studies, E. coli or P. aeruginosa suspen-
sions were prepared in HEPES buffer (10 mM HEPES, 150 mM
NaCl, pH 7.4) at 107 cfu/ml, and Ctn or Ctn(15–34) was added
at different concentrations. Treated and untreated suspensions
were injected into zeta cells and allowed to equilibrate at
25 °C for 15 min, and measurements were acquired on a
Zetasizer Nano ZS (Malvern Instruments, Worcestershire,
UK).  potential was calculated from the mean of 15 mea-
surements, using the Smoluchowski equation as described
previously (55). Experiments were performed in triplicate.
Viability and membrane permeabilization correlation studies
To determine bacterial viability and membrane permeabiliza-
tion, bacterial suspensions at 108 cfu/ml in MHBII were centri-
fuged 10 min at 4000  g and diluted to 5  105 cfu/ml in HEPES
buffer. Incubation with 2-fold serial peptide dilutions was done at
37 °C and 200 rpm, for 90 min for E. coli and 60 min for P. aerugi-
nosa. Untreated bacteria were used as negative control. To esti-
mate the percentage of permeabilized bacteria and percentage of
viable bacteria, each sample was respectively evaluated by FCA and
colony count methods using protocols described previously (42).
Membrane permeabilization induced by RhB-labeled peptides
Samples for FCA were prepared as described above. Data were
acquired on a BD FACSAria III cell sorter (BD Biosciences) using
blue (488-nm) and yellow-green (561-nm) lasers and emission fil-
ters BP530/30 (LP505) and BP586/15 to detect SYTOX Green
and RhB, respectively. 5000 events corresponding to bacterial pop-
ulation as previously defined by forward scatter and side scatter
were recorded. Experiments were performed in triplicate.
Peptide uptake and bacterial death kinetics
Peptide uptake and bacterial permeabilization were moni-
tored in real time as described elsewhere (34). Briefly, a 108
cfu/ml bacterial inoculum was prepared in MHBII, centrifuged
for 10 min at 4000  g, and diluted to 107 cfu/ml on HEPES
buffer. Dead bacteria were prepared by incubation at 37 °C with
70% (v/v) isopropyl alcohol for 60 min. SYTOX Green was
added to the bacterial suspension at 0.05 M final concentra-
tion and incubated for at least 10 min. Ctn, RhB-Ctn, Ctn(15–
34), or RhB-Ctn(15–34) was added to a final concentration
equal to its MBC. Measurements were performed on a Fortessa
X-20 instrument (BD Biosciences) using blue (488 nm) and
yellow-green (561 nm) lasers and emission filters BP530/30
(LP505) and BP586/15 to detect SYTOX Green and RhB,
respectively. A total of 10,000 events were recorded for con-
trols. For kinetic experiments, acquisition was done for 90 min
immediately after the peptide addition. A control of untreated
E. coli was also recorded for 90 min to ensure that bacteria
remained alive during the total acquisition (see Fig. S8b). The
bacterial population was selected according to the forward scat-
ter/side scatter and the positive/negative SYTOX Green gates
(SG	/SG), and positive/negative RhB gates (RhB	/RhB)
were established using controls. For kinetic analysis, events (#)
on the SG	 and SG gates were clustered for time intervals (n)
equal to 1 s, and the number of events for each interval (#n) was
counted. The ratios of permeabilized bacteria (P) and peptide
uptake (Y) (bound to the membrane or internalized) for each n












	  #n on RhB

(Eq. 2)
Estimated percentages of permeabilized bacteria and peptide
uptake for each n were calculated by the following equations.
% permeabilized bacteria at n 
Pn  Plive
Pdead  Plive
	 100 (Eq. 3)
% peptide uptake at n 
Un  Ulive
Udead  Ulive
	 100 (Eq. 4)
The percentage of permeabilized bacteria was corrected using
the equation derived from the calibration curve shown on Fig.
S8a, obtained by combining known percentages of dead and
live bacteria.
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Data were fitted to the two-state model described previously
(34), using the following equation,
y  y0  Bl  y0 	 1  k
1e  k2x  k2e  k
1xk2  k
1  (Eq. 5)
where k
1  k0xf; y0  initial % permeabilized bacteria; Bl 
final % permeabilized bacteria; k2  permeabilization kinetic
constant; k0  membrane attachment constant; and f  coop-
erativity binding factor.
Confocal microscopy
An E. coli suspension was prepared at 108 cfu/ml in MHBII,
centrifuged for 10 min at 4000  g, and diluted to 107 cfu/ml on
HEPES buffer. RhB-labeled or unlabeled peptides were added
to the bacterial suspensions at a final concentration equal to their
MBC, and the samples were incubated at 37 °C and 200 rpm for 90
min. Untreated bacteria were used as a control. After incubation,
samples were placed on ice, and SYTOX Green was added at 5
M final concentration. Samples were placed on an ibiTreat-
coated 8-well -slide (Ibidi, Munich, Germany) before imaging.
Acquisition was made on a confocal point-scanning Zeiss
LSM 880 microscope (Carl Zeiss, Jena, Germany) equipped
with an alpha Plan-Apochromat 100 oil immersion objective
(1.46 numerical aperture). The 488-nm line from an argon
laser and the DPSS 561-20 laser were used to excite SYTOX
Green and RhB, respectively. In the normal confocal mode,
0.6 zoom images were recorded at 1024  1024 resolution.
In the Airyscan superresolution mode, 5.5 zoom was
applied to select one single bacteria cell, and the optimal
resolution was selected. ZEN software was used for image
acquisition and Airyscan image processing. Fiji software was
used for background subtraction and brightness and con-
trast adjust (identically for compared image sets). At least 12
total images were acquired in three independent replicates.
Atomic force microscopy
Morphological changes on E. coli cells induced by Ctn and
Ctn(15–34) were visualized by AFM imaging. 108 cfu/ml suspen-
sions were prepared on MHBII, centrifuged for 10 min at 4000g,
and diluted to 107 cfu/ml in HEPES buffer. Bacterial suspensions in
the absence or the presence of Ctn or Ctn(15–34) at their MBC
were incubated at 37 °C and 200 rpm for 90 min. Untreated bacte-
ria were used as a control. Slide preparation, image acquisition,
and processing were as described previously (32).
Binding affinity for LTA and LPS
Neutralization of LTA and LPS by Ctn(15–34) or RhB-
Ctn(15–34) was examined using the end-point chromogenic
LAL assay kit (QLC-1000, Lonza) following the same protocol
as before (36).
Liposome preparation
POPC; POPS; POPG; POPE; E. coli polar lipid extract con-
taining PE-phospholipids, PG-phospholipids, and cardiolipin
in the proportion 67:23.2:9.8 (w/w/w); and octadecanoyl SM
extracted from porcine brain were purchased from Avanti
Polar Lipids (Alabaster, AL). Lipids were solubilized in spec-
troscopy-grade chloroform and mixed as required to prepare
defined lipid compositions. LUVs (100-nm diameter) or SUVs
(50-nm diameter) were prepared in HEPES buffer by extrusion,
as described previously (56). LUVs were used in fluorescence
spectroscopy assays, whereas SUVs were used for SPR studies
to facilitate bilayer deposition on the chip surface.
Vesicle leakage assay
Content leakage from POPC or POPC/POPS (80:20 molar
ratio) vesicles was quantified by CF fluorescence dequenching
using LUVs loaded with 50 mM CF as described previously (57).
Briefly, 2-fold dilutions of peptides (starting with 10 M) were
incubated for 20 min with LUVs (5 M of lipid concentration) in
HEPES buffer. Fluorescence emission intensity (excitation at
494 nm and emission at 515 nm) was measured in an M1000
microplate reader (Tecan, Männedorf, Switzerland), and the
leakage percentage was calculated as described previously (57).
Interactions with lipid bilayers
Peptide-membrane interactions were monitored by SPR at
25 °C with a L1 biosensor chip in a Biacore 3000 instrument (GE
Healthcare Australia, Parramatta, Australia). SUVs composed of
POPC, POPC/POPE (80:20 molar ratio), POPC/POPG (80:20),
POPC/POPG (60:40), POPC/Chol/SM (27:33:40), POPC/POPS
(80:20), POPC/POPS (60:40), POPC/POPS/POPE (60:20:20), or
E. coli polar extract were prepared using HEPES buffer and depos-
ited onto a L1 chip by injecting SUV suspensions with 0.5 mM lipid
at a flow rate of 2 l/min for 40 min. Peptides were injected over
the lipid bilayers at a flow rate of 5 l/min for 180 s (association
phase), and dissociation was monitored for 600 s (58, 59). HEPES
was used as running buffer, and the chip was regenerated as before
(60). All solutions were freshly prepared and filtered using a
0.22-m pore size filter. The response units were normalized to
peptide/lipid ratio as described previously (58).
Hemolytic studies
Fresh human blood was collected from three healthy donors
following protocols approved by the Human Research Ethics Unit
at the University of Queensland. RBCs were isolated by centrifu-
gation (1500  g, 1 min), washed three times, and resus-
pended in PBS (137 mM NaCl, 2.7 mm KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4) at 0.25% (v/v). RBC suspensions were incu-
bated with increasing concentrations of Ctn(15–34) or with
RhB-Ctn(15–34) for 1 h at 37 °C, and the percentage of
hemolysis was quantified by the 405-nm absorbance of
released hemoglobin. Samples incubated with PBS or with
Triton X-100 0.1% (v/v) were used to define 0 and 100% of
hemolysis, respectively, as described previously (61). Melit-
tin, a hemolytic peptide, was included as a control.
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